السهم فتح جاب بتاريخ ١٣ يونيو بارتفاع ١٠٠٪ وأغلق على انخفاض
اليوم به ارتفاع بالبري ماركت للمتابعة ارتفاع ٤٠٪ !!!
اهداف السهم 2.46
2.83
3.20
السبب تلقيه دفعه مالية من مستثمر بناء علي نتائج بحوث احد الادوية لديهم مقابل مضاعفه مبلغ الاستثمار مستقبلا في حال النتائج ايجابيه
Shares of Eleven Biotherapeutics Inc.
EBIO, +40.31% rocketed 66% in premarket trade Friday, after the said it would be entitled to receive a $22.5 million milestone payment related to its eye disease treatment. The biopharmaceutical company said its investigational new drug application for EBI-031, a treatment for diabetic macular edema, has become effective, which was a milestone in
a license deal the company entered with F. Hoffman-La Roche Ltd. last month. The agreement says Eleven could receive up to $262.5 million if certain regulatory, development and commercialization milestones are met. Eleven's stock had soared nearly six-fold in the past three months through Thursday, but was still down 35% year to date.